P/F/224. Dissertation. GlaxoSmithKlines merger: economic benefit and value to a final company?

This dissertation performs a research of a merger case of GlaxoSmithKline, a pharmaceutical company and examines the impact of the merger on the companys performance in terms of economic benefits and value creation. The research is performed on a base of the companys financial data and publications, literature review in the related area and of the questionnaire survey. First, strategic and economic reasons for mergers in the whole were considered, for this, the empirical evidence of the case companys financial performance was highlighted. Next, benefits of GlaxoSmithKline after the merger have been analysed from the economic, functional, financial and strategic perspectives. Finally, the paper makes a summary and concludes about the benefits the company received after the merge in the long-term range.